Blair William & Co. IL Sells 35,728 Shares of Synthetic Biologics Inc (SYN)
Blair William & Co. IL reduced its position in Synthetic Biologics Inc (NYSEMKT:SYN) by 2.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,602,298 shares of the company’s stock after selling 35,728 shares during the period. Blair William & Co. IL owned approximately 1.25% of Synthetic Biologics worth $906,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Synthetic Biologics during the fourth quarter valued at approximately $356,000. Bank of New York Mellon Corp increased its stake in shares of Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the period. UBS Group AG increased its stake in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the period. Creative Planning increased its stake in shares of Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares during the period. Finally, LMR Partners LLP purchased a new stake in shares of Synthetic Biologics during the second quarter valued at approximately $194,000.
Synthetic Biologics Inc (NYSEMKT SYN) opened at 0.7238 on Thursday. The company’s market cap is $92.83 million. Synthetic Biologics Inc has a 52 week low of $0.41 and a 52 week high of $1.90. The stock has a 50 day moving average of $0.55 and a 200 day moving average of $0.62.
Synthetic Biologics (NYSEMKT:SYN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.03. Equities research analysts predict that Synthetic Biologics Inc will post ($0.17) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Blair William & Co. IL Sells 35,728 Shares of Synthetic Biologics Inc (SYN)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/blair-william-co-il-sells-35728-shares-of-synthetic-biologics-inc-syn/1533303.html.
Several equities analysts have issued reports on SYN shares. Zacks Investment Research cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, William Blair restated an “outperform” rating and set a $5.00 target price on shares of Synthetic Biologics in a research note on Monday, May 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Synthetic Biologics has a consensus rating of “Hold” and an average price target of $4.39.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.